Protocol Ledger

NCT02864953 · Phase III · TERMINATED

Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction

Interventional Phase III clinical trial protocol NCT02864953 sponsored by Remedy Pharmaceuticals in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-08-29 Enrollment: 535 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT02864953
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)535 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT02864953
Protocol FieldVerified Registry Value
NCT IdentifierNCT02864953
Consolidated Lead SponsorRemedy Pharmaceuticals
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment535 participants (ACTUAL)
Registered Start Date2018-08-29
WhyStopped ClassificationSafety / Toxicity / Adverse Events

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI